Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial
Jessica Gong, Katie Harris, Maree Hackett, Sanne AE Peters, Henry Brodaty, Mark Cooper, Pavel Hamet, Stephen Harrap, Giuseppe Mancia, Stephen MacMahon, John Chalmers, Mark Woodward
DIABETES OBESITY & METABOLISM | WILEY | Published : 2021
AIM: To estimate the associations between risk factors and cognitive decline (CD)/dementia, and the sex differences in these risk factors in individuals with type 2 diabetes, while accounting for the competing risk of death. MATERIALS AND METHODS: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial of 11,140 individuals with type 2 diabetes was used to estimate the odds of CD/dementia using multinomial logistic regression. RESULTS: During a median 5-year follow-up, 1827 participants (43.2% women) had CD/dementia (1718 with CD only; 21 with dementia only; 88 with CD and dementia), and 929 (31.0% women) died without CD/deme..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by Australian National Health and Medical Research Council
The ADVANCE trial (ClinicalTrials.gov registration no. NCT00145925) was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia (project grant ID 211086 and programme grant IDs 358395 and 571281) and from Servier. JG is supported by a Scientia PhD Scholarship from the University of New South Wales. MH is supported by an NHMRC fellowship. MW is supported by an Australian National Health and Medical Research Council Investigator Grant (APP1174120) and Program Grant (APP1149987).